Allakos Inc

Allakos — Investor Day (February 2022)

81 slides from Allakos's investor day presentation, Feb 15, 2022

  1. Slide 1: Corporate Update February 15, 2022

    Slide 1: Corporate Update February 15, 2022

    Corporate Update February 15, 2022 Exhibit 99.1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b

  3. Slide 3: Allakos Investor Day Agenda

    Slide 3: Allakos Investor Day Agenda

    Robert Alexander, PhD Introductions Craig A. Paterson, MD Review of KRYPTOS and ENIGMA 2 Clinical Studies Evan S. Dellon, MD, MPH Physician Perspective Robert Alexander, PhD Atopic Dermatitis and Chronic Spontaneous Urticaria Marcus Maurer, MD Physician Perspective Brad A. Youngblood, PhD Pipeline S

  4. Slide 4: Review of KRYPTOS (EoE) and ENIGMA2 (EG/EoD) Clinical Studies

    Slide 4: Review of KRYPTOS (EoE) and ENIGMA2 (EG/EoD) Clinical Studies

    Review of KRYPTOS (EoE) and ENIGMA2 (EG/EoD) Clinical Studies Craig A. Paterson, MD CMO – Allakos Inc.

  5. Slide 5: KRYPTOS Phase 2/3 EoE Study Design

    Slide 5: KRYPTOS Phase 2/3 EoE Study Design

    KRYPTOS Phase 2/3 EoE Study Design Multi-center, randomized, DB, placebo-controlled Active moderate to severe symptoms Dysphagia Symptom Questionnaire (DSQ) ≥12 Biopsy confirmed EoE Esophagus: ≥15 eos/high power field (hpf) in 1 hpf 276 patients dosed (1:1:1 randomization) High dose lirentelimab 1 +

  6. Slide 6: Histology Co-primary Endpoint: Eosinophil Responders

    Slide 6: Histology Co-primary Endpoint: Eosinophil Responders

    Histology Co-primary Endpoint: Eosinophil Responders * Difference from placebo p-values <0.0001 derived using Fisher’s Exact Test 1 ITT: Missing data was treated as non-responders High Dose * (80/91) (86/93) Low Dose Lirentelimab * Placebo (10/92) * (80/80) (86/87) * (10/88) Proportion of EoE Eosino

  7. Slide 7: Complete Histologic Responders

    Slide 7: Complete Histologic Responders

    Complete Histologic Responders * Difference from placebo p-values <0.0001 derived using Fisher’s Exact Test 1 Observed data Secondary Endpoint: Complete Histologic Remission at Week 241 * (77/80) (82/87) * (4/88) High Dose Low Dose Placebo Lirentelimab % of Patients Achieved Peak Esophageal Eos ≤1 E

  8. Slide 8: Symptom Co-primary Endpoint: Change in DSQ

    Slide 8: Symptom Co-primary Endpoint: Change in DSQ

    Symptom Co-primary Endpoint: Change in DSQ * LS Means and HD lirentelimab from placebo p-values derived from ANCOVA model Absolute Change LS Mean Change from BL 35.2 34.2 36.4 BL DSQ = Change in DSQ at Weeks 23-24 Percent Change Mean % Change from BL High Dose (n=82) Low Dose (n=88) Placebo (n=89) H

  9. Slide 9: Baseline Demographics and Patient Characteristics

    Slide 9: Baseline Demographics and Patient Characteristics

    Baseline Demographics and Patient Characteristics 1 Asthma, allergic rhinitis, atopic dermatitis and/or food allergy Patient Characteristics HD Lirentelimab (n=91) LD Lirentelimab (n=93) Placebo (n=92) Age, median years (range) 29 (12 - 69) 34 (12 - 67) 32 (12 - 70) Female sex, % (n) 29% (26) 43% (4

  10. Slide 10: Eosinophilic Threshold for Establishing Moderate-Severe EoE

    Slide 10: Eosinophilic Threshold for Establishing Moderate-Severe EoE

    Eosinophilic Threshold for Establishing Moderate-Severe EoE Fig 1. Rothenberg ME. J Allergy Clin Immunol 2001;108:891-4. Primary EoE

  11. Slide 11: Baseline Demographics: By Peak Esophageal Eosinophils

    Slide 11: Baseline Demographics: By Peak Esophageal Eosinophils

    Baseline Demographics and Patient Characteristics: By Peak Esophageal Eosinophils SOURCE: Stein ML, Collins MH, et al. J Allergy Clin Immunol 2006;118:1312-3219; Noel RJ, Putnam PE, Rothenberg ME. N Engl J Med 2004;351:940-941. Rothenberg ME, J Allergy Clin Immunol 2001 Patient Characteristics Peak

  12. Slide 12: DSQ Response by Baseline Peak Eosinophil Count

    Slide 12: DSQ Response by Baseline Peak Eosinophil Count

    DSQ Response in Patients by Baseline Peak Eosinophil Count Baseline Eos ≤24/hpf Mean Change from BL Lirentelimab 36.1 34.2 37.9 BL DSQ = * LS Means and HD lirentelimab from placebo p-values derived from MMRM model Baseline Eos >24 /hpf Lirentelimab 35.0 34.2 36.1 BL DSQ = * Change in DSQ by Baseline

  13. Slide 13: DSQ Response by Baseline Peak Eosinophil Count (Percent Change)

    Slide 13: DSQ Response by Baseline Peak Eosinophil Count (Percent Change)

    DSQ Response in Patients by Baseline Peak Eosinophil Count Baseline Eos >24 /hpf Baseline Eos ≤24/hpf Lirentelimab Lirentelimab * LS Means and HD lirentelimab from placebo p-values derived from MMRM model * Mean % Change from BL % Change in DSQ by Baseline Peak Esophageal Eos Level at Week 23-24 Pla

  14. Slide 14: Study Results in Adolescents

    Slide 14: Study Results in Adolescents

    Study Results in Adolescents Age 12 - 17 years

  15. Slide 15: Baseline Demographics: Adolescents

    Slide 15: Baseline Demographics: Adolescents

    Baseline Demographics and Patient Characteristics: Adolescents 1 Asthma, allergic rhinitis, atopic dermatitis and/or food allergy Patient Characteristics HD Lirentelimab (n=17) LD Lirentelimab (n=17) Placebo (n=17) Age, median years (range) 14 (12 - 17) 15 (12 - 17) 14 (12 - 17) Female sex, % (n) 12

  16. Slide 16: Histologic Response in Adolescents

    Slide 16: Histologic Response in Adolescents

    Histologic Response in Adolescents * Difference from placebo p-values <0.0001 derived using Fisher’s Exact Test 1 Observed data * * Lirentelimab Placebo High Dose Low Dose Proportion of Eosinophil Responders in Adolescents1 Achieved Peak Esophageal Eos ≤6 Eos/hpf at Week 24 % of Patients

  17. Slide 17: DSQ Response in Adolescents

    Slide 17: DSQ Response in Adolescents

    DSQ Response in Adolescents * LS Means and HD lirentelimab from placebo p-values derived from ANCOVA model 1 Observed data Mean % Change from BL Mean Change from BL Percent Change Absolute Change Change in DSQ1 at Weeks 23-24 in Adolescents *p=0.1316 *p=0.0474 Lirentelimab 33.2 34.6 35.2 BL DSQ = Pl

  18. Slide 18: Safety Summary

    Slide 18: Safety Summary

    Safety Summary

  19. Slide 19: KRYPTOS Safety Summary

    Slide 19: KRYPTOS Safety Summary

    KRYPTOS Safety Summary n (%) of Patients HD Lirentelimab (n=91) LD Lirentelimab (n=93) Placebo (n=92) ≥1 Treatment-Emergent Adverse Event (TEAE) 61 (67.0%) 65 (69.9%) 53 (57.6%) Infusion related reaction 35 (38.5%) 24 (25.8%) 11 (12.0%) Headache 6 (6.6%) 8 (8.6%) 6 (6.5%) Drug-related Serious AEs: 2

  20. Slide 20: Open-Label Extension

    Slide 20: Open-Label Extension

    20 Open-Label Extension

  21. Slide 21: Durability of Effect in Open-Label Extension

    Slide 21: Durability of Effect in Open-Label Extension

    Durability of Effect in Open-Label Extension * LS Means and p-values derived from MMRM model Baseline DSQ Score, mean ± SD Placebo: 35.0±12.5; LD Lirentelimab: 36.1±12.3; HD Lirentelimab: 34.2±12.2 Absolute Change Absolute Change Mean (SE) / Mean (SD) Change in DSQ from Baseline: Patients with BL Es

  22. Slide 22: Summary & Conclusions

    Slide 22: Summary & Conclusions

    Summary & Conclusions KRYPTOS Phase 2/3 study included patients with questionable EoE diagnosis Clear activity observed in moderate-to-severe EoE patients Clear activity in adolescents Durability of effect observed in interim analysis of open-label extension Lirentelimab was well-tolerated in both a

  23. Slide 23: Review of ENIGMA2 Phase 3 EG/EoD Study

    Slide 23: Review of ENIGMA2 Phase 3 EG/EoD Study

    Review of ENIGMA2 Phase 3 EG/EoD Study

  24. Slide 24: ENIGMA2 Phase 3 EG/EoD Study Design

    Slide 24: ENIGMA2 Phase 3 EG/EoD Study Design

    ENIGMA2 Phase 3 EG/EoD Study Design Multi-center, randomized, DB, placebo-controlled Active moderate to severe symptoms Biopsy confirmed EG and/or EoD Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 180 adult patients (1:1 randomization) Lirentelimab 1 + 3 + 3 + 3

  25. Slide 25: Histology Co-Primary Endpoint: Eosinophil Responders

    Slide 25: Histology Co-Primary Endpoint: Eosinophil Responders

    Histology Co-Primary Endpoint: Eosinophil Responders * Difference from placebo p-values <0.0001 derived using Fisher’s Exact Test 1 Eosinophil response criteria: ≤4 eos/hpf in top 5 gastric hpfs and/or ≤15 eos/hpf in top 3 duodenal hpfs 2 ITT: Missing data was treated as non-responders 98% mean redu

  26. Slide 26: Symptom Co-Primary Endpoint: TSS6

    Slide 26: Symptom Co-Primary Endpoint: TSS6

    Symptom Co-Primary Endpoint: TSS6 1 TSS6 Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping Absolute Change LS Mean Change from BL Change in Total Symptom Score1 Percent Change Lirentelimab (n=75) Placebo (n=75) 27.7 29.5 BL TSS = Lirentelimab (n=75) Plac

  27. Slide 27: Responder Analysis Suggests Clinical Activity

    Slide 27: Responder Analysis Suggests Clinical Activity

    Responder Analysis Suggests Clinical Activity Secondary Endpoint: Proportion of Patients Achieving TSS Thresholds at Weeks 23-241 Lirentelimab (n=75) Placebo (n=75) ≥30% Reduction % (n) of Patients ≥50% Reduction ≥70% Reduction ≥90% Reduction (42) (45) (36) (29) (26) (18) (11) (6) 1 Observed data

  28. Slide 28: Baseline Demographics: ENIGMA1 and ENIGMA2

    Slide 28: Baseline Demographics: ENIGMA1 and ENIGMA2

    Baseline Demographics & Patient Characteristics: ENIGMA1 and ENIGMA2 Patient Characteristics Ph2 ENIGMA1 (E1) Ph3 ENIGMA2 Patient Characteristics n=65 AK002 n=91 Placebo n=89 Age, median years (range) 40 (18-74) 43 (17-77) 41 (18-78) Female sex, % (n) 62% (40) 62% (56) 69% (61) History of EoE, % (n)

  29. Slide 29: Baseline Demographics: Site Comparison

    Slide 29: Baseline Demographics: Site Comparison

    Baseline Demographics & Patient Characteristics: Site Comparison Patient Characteristics Ph2 ENIGMA1 (E1) Ph3 ENIGMA2 Patient Characteristics n=65 E1 Sites n=81 Non-E1 Sites n=99 Age, median years (range) 40 (18-74) 45 (18-77) 40 (17-78) Female sex, % (n) 62% (40) 59% (48) 70% (69) History of EoE, %

  30. Slide 30: Consistent Effects Observed in ENIGMA1 Site Patients

    Slide 30: Consistent Effects Observed in ENIGMA1 Site Patients

    Consistent Effects Observed in ENIGMA1 Site Patients Mean Change in TSS6 from Baseline at End of Treatment1 * LS Means and p-values derived from ANCOVA/MMRM models 1 ENIGMA1: mean TSS6 change from BL to Weeks 13-14; ENIGMA2: mean TSS6 change from BL to Weeks 23-24 Mean TSS6 Change from BL Placebo (n

  31. Slide 31: Similar Results Seen in ENIGMA1 Site Patients

    Slide 31: Similar Results Seen in ENIGMA1 Site Patients

    ≥30% Reduction % (n) of Patients ≥50% Reduction ≥70% Reduction ≥90% Reduction Lirentelimab (n=20) Placebo (n=20) ≥30% Reduction ≥50% Reduction ≥70% Reduction ≥90% Reduction Lirentelimab (n=38) Placebo (n=34) Similar Results Seen in ENIGMA1 Site Patients Proportion of Patients Achieving TSS6 Threshol

  32. Slide 32: ENIGMA2: Non-ENIGMA1 Site Patients

    Slide 32: ENIGMA2: Non-ENIGMA1 Site Patients

    ENIGMA2: Non-ENIGMA1 Site Patients Mean Change in TSS6 from Baseline at End of Treatment Placebo (n=43) Lirentelimab (n=42) ENIGMA2: Non-E1 Site Pts 29.5 27.7 BL TSS6 = Mean TSS6 Change from BL

  33. Slide 33: ENIGMA2: Non-ENIGMA1 Site Patients TSS6 Thresholds

    Slide 33: ENIGMA2: Non-ENIGMA1 Site Patients TSS6 Thresholds

    ENIGMA2: Non-ENIGMA1 Site Patients Proportion of Patients Achieving TSS6 Thresholds at Weeks 23-24: Non-E1 Site Pts ≥30% Reduction % (n) of Patients ≥50% Reduction ≥70% Reduction ≥90% Reduction Lirentelimab (n=42) Placebo (n=43)

  34. Slide 34: Safety Summary

    Slide 34: Safety Summary

    34 Safety Summary

  35. Slide 35: ENIGMA2 Safety Summary

    Slide 35: ENIGMA2 Safety Summary

    ENIGMA2 Safety Summary No drug-related Serious AEs Safety risk profile overall was consistent with previously reported safety profile in ENIGMA1 and other lirentelimab studies to date n (%) of Patients Lirentelimab (n=91) Placebo (n=89) ≥1 Treatment-Emergent Adverse Event (TEAE) 65 (71.4%) 57 (64.0%

  36. Slide 36: Open Label Extension

    Slide 36: Open Label Extension

    36 Open Label Extension

  37. Slide 37: Durability of Effect in Open-Label Extension (E1 Site Patients)

    Slide 37: Durability of Effect in Open-Label Extension (E1 Site Patients)

    Durability of Effect in Open-Label Extension (E1 Site Patients) * LS Means and p-values derived from MMRM model Baseline TSS6 Score, mean ± SD Placebo: 27.8±12.1; Lirentelimab: 29.4±11.4 Absolute Change Absolute Change from BL Mean (SE) / Mean (SD) Change in TSS6 from Baseline: E1 Site Patients 34 -

  38. Slide 38: Summary of ENIGMA2

    Slide 38: Summary of ENIGMA2

    Summary of ENIGMA2 ENIGMA2 patients with similar characteristics to those included in Phase 2 reproduced original study results Key patient characteristics identified include: Higher tissue eos counts Higher peripheral blood eos counts Higher IgE levels Durability of effect observed in interim analy

  39. Slide 39: Phase 3 EoD Study

    Slide 39: Phase 3 EoD Study

    Phase 3 EoD Study

  40. Slide 40: EoD Phase 3 Study Design

    Slide 40: EoD Phase 3 Study Design

    EoD Phase 3 Study Design Multi-center, randomized, double-blind, placebo-controlled study in EoD Active moderate to severe symptoms Biopsy confirmed EoD ± colonic involvement Duodenum: ≥30 eos/hpf in 3 hpfs Stomach: <30 eos/high powered field (hpf) in 5 hpfs (Do NOT have EG) Colonic involvement asse

  41. Slide 41: Phase 3 EoD Study Update

    Slide 41: Phase 3 EoD Study Update

    Phase 3 EoD Study Update Fully enrolled (N=93) Study will complete mid-2022 Population enrolled is similar to ENIGMA2 population Data from EoD study will inform correspondence with the FDA

  42. Slide 42: Next Steps in EGIDs

    Slide 42: Next Steps in EGIDs

    Next Steps in EGIDs EoE End of Phase 2 meeting Update market post FDA meeting EG/EoD Await and incorporate 021 EoD study data Plan to meet with FDA to discuss data and findings Update the market post the FDA meeting

  43. Slide 43: Professor Evan S. Dellon, MD MPH

    Slide 43: Professor Evan S. Dellon, MD MPH

    Professor Evan S. Dellon, MD MPH TITLE: Professor of Medicine, Gastroenterology & Epidemiology Director, Center for Esophageal Diseases and Swallowing Director, CGIBD Biostatistics and Clinical Research Core INSTITUTION: University of North Carolina School of Medicine SPECIALTY: Gastroenterology FOC

  44. Slide 44: Lirentelimab for Inflammatory Skin Diseases

    Slide 44: Lirentelimab for Inflammatory Skin Diseases

    Lirentelimab for Inflammatory Skin Diseases Robert Alexander, PhD CEO

  45. Slide 45: Strong Scientific Rationale for Targeting Mast Cells and Eosinophils

    Slide 45: Strong Scientific Rationale for Targeting Mast Cells and Eosinophils

    Strong Scientific Rationale for Targeting Mast Cells and Eosinophils in Chronic Inflammatory Skin Diseases Atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) are characterized by inflamed itchy skin Improvements observed in patients with concomitant atopic dermatitis and chronic urticari

  46. Slide 46: AK002 Mast Cell Inhibition

    Slide 46: AK002 Mast Cell Inhibition

    AK002 Mast Cell Inhibition

  47. Slide 47: Lirentelimab Broadly Inhibits Mast Cell Activation

    Slide 47: Lirentelimab Broadly Inhibits Mast Cell Activation

    Lirentelimab Broadly Inhibits Mast Cell Activation Lirentelimab targets multiple disease-driving pathways through mast cell inhibition Mast Cell Inhibition

  48. Slide 48: Lirentelimab Inhibits IL-33-Mediated Mast Cell Activation

    Slide 48: Lirentelimab Inhibits IL-33-Mediated Mast Cell Activation

    Lirentelimab Inhibits IL-33-Mediated Mast Cell Activation Transcriptome of IL-33-Activated Mast Cells Resting MCs Isotype Control+ IL-33 Anti-S8 + IL-33 SOURCE: Schanin, J et al. Mucosal Immunology 2020; Korver, W et al. Frontiers in Immunology 2022

  49. Slide 49: Lirentelimab Inhibits IgE-Mediated Mast Cell Activation

    Slide 49: Lirentelimab Inhibits IgE-Mediated Mast Cell Activation

    Lirentelimab Inhibits IgE-Mediated Mast Cell Activation Phospho-Proteome of IgE-Activated Mast Cells Resting MCs Isotype Control + IgE Anti-S8 + IgE Syk: Y519 Ship1: S1090 Gab2: Y632 Syk: Y520 PKCd: Y311 Dapp1: S141 Ship1: S1130 Ahnak: S699 Dapp1: Y139 SOURCE: Schanin, J et al. Mucosal Immunology 20

  50. Slide 50: Lirentelimab Inhibits MRGPRX2-Mediated Mast Cell Activation

    Slide 50: Lirentelimab Inhibits MRGPRX2-Mediated Mast Cell Activation

    Lirentelimab Inhibits MRGPRX2-Mediated Mast Cell Activation Lirentelimab inhibits key driver of mast cell activation in chronic disease Mouse Model of MRGPRX2-mediated Inflammation Mast Cell-Derived Inflammatory Cytokines 0h Substance P IP Injection 4h 1h Isotype or lirentelimab Evaluate Inflammatio

  51. Slide 51: Lirentelimab Reduces TLR-mediated Inflammation In Vivo

    Slide 51: Lirentelimab Reduces TLR-mediated Inflammation In Vivo

    Lirentelimab Reduces TLR-mediated Inflammation In Vivo Day 1 Intranasal TLR3 agonist (Poly (I:C)) Day 3 Isotype or Anti-S8 Evaluate Inflammation Vehicle ISO + poly (I:C) Anti-S8 + poly (I:C) Lirentelimab treatment significantly reduces TLR-mediated airway inflammation, including IL-6, TNF, CCL2/MCP1

  52. Slide 52: Lirentelimab for Atopic Dermatitis

    Slide 52: Lirentelimab for Atopic Dermatitis

    Lirentelimab for Atopic Dermatitis

  53. Slide 53: AD Lesional Biopsies Show Evidence of MC and Eosinophil Activity

    Slide 53: AD Lesional Biopsies Show Evidence of MC and Eosinophil Activity

    AD Lesional Biopsies Show Evidence of MC and Eosinophil Activity Immune Cell Numbers Disease Biomarkers Mast Cell Activation Lirentelimab reduces levels of CPA3, CCL17/TARC and CCL26/Eotaxin-3 CCL26 / Eotaxin-3 CCL17 / TARC CPA3 Eosinophils Mast Cells SOURCE: Youngblood, BA et al JCI Insights 2019;

  54. Slide 54: Reduction in Clinically-Relevant Cytokines

    Slide 54: Reduction in Clinically-Relevant Cytokines

    Reduction in Clinically-Relevant Cytokines SOURCE: Data on file. Manuscript submitted Ocular Inflammation via Tear Cytokines (Ph1b Severe Allergic Conjunctivitis) Last Dose Last Dose Last Dose Last Dose IL-4 IL-13 CCL26 / Eotaxin-3 CCL3 / MIP-1

  55. Slide 55: Improvement in Concomitant Atopic Dermatitis

    Slide 55: Improvement in Concomitant Atopic Dermatitis

    Improvement in Concomitant Atopic Dermatitis SOURCE: ENIGMA2 data on file. SAC manuscript submitted Median % Change from BL Weeks 21-22 Placebo (n=4) Lirentelimab (n=5) Atopic Dermatitis (Open-Label SAC Study) Lirentelimab (n=11) Atopic Dermatitis (ENIGMA2)

  56. Slide 56: Phase 2 AD Study Design

    Slide 56: Phase 2 AD Study Design

    Phase 2 AD Study Design Multi-center, randomized, DB, placebo-controlled Chronic disease that has been present ≥3 years EASI score ≥16 Involvement of ≥10% of body surface area IGA score ≥3 Inadequate control by topical treatments Dupilumab, tralikinumab, and JAK naïve 120 adult patients (1:1 randomi

  57. Slide 57: Chronic Spontaneous Urticaria

    Slide 57: Chronic Spontaneous Urticaria

    Chronic Spontaneous Urticaria

  58. Slide 58: Phase 2a Chronic Urticaria Study

    Slide 58: Phase 2a Chronic Urticaria Study

    Phase 2a Chronic Urticaria Study Open-label in Chronic Urticaria Uncontrolled CU (UCT<12) Diagnosis of CU for at least 3 months, refractory to antihistamine treatment in single or 4-fold dosage 45 patients – 4 arms Omalizumab-naïve CSU Omalizumab-refractory CSU Cholinergic urticaria Symptomatic derm

  59. Slide 59: Phase 2a Chronic Urticaria Study – Results in CSU

    Slide 59: Phase 2a Chronic Urticaria Study – Results in CSU

    Phase 2a Chronic Urticaria Study – Results in CSU Omalizumab Naïve CSU Patients (n=13) Baseline Week 22 Omalizumab Refractory CSU Patients Receiving All 6 Doses (n=7) SOURCE: Altrichter S, Staubach P, Pasha M, et al. J Allergy Clin Immunol 2022 (In Press) UAS7 Mean Score ±95% CI Baseline Week 22 ***

  60. Slide 60: Phase 2b Chronic Spontaneous Urticaria Study

    Slide 60: Phase 2b Chronic Spontaneous Urticaria Study

    Phase 2b Chronic Spontaneous Urticaria Study Multi-center, randomized, DB, placebo-controlled Active moderate-to-severe symptoms CSU diagnosis with onset ≥6 months prior to screening Diagnosis of CSU refractory to antihistamines Presence of itch and hives despite current use of antihistamines UAS7 s

  61. Slide 61: Lirentelimab for Inflammatory Skin Diseases

    Slide 61: Lirentelimab for Inflammatory Skin Diseases

    Lirentelimab for Inflammatory Skin Diseases Mast cells and eosinophils are key drivers of inflammatory skin diseases Lirentelimab has demonstrated broad inhibition of mast cell and eosinophil activity in vivo and ex vivo studies Clinical proof of concept in patients with CSU and concomitant AD

  62. Slide 62: Professor Marcus Maurer, MD

    Slide 62: Professor Marcus Maurer, MD

    Professor Marcus Maurer, MD TITLE: Professor of Dermatology and Allergy Director of Research - Allergie Centrum Charité INSTITUTION: Charité Universitätsmedizin Berlin SPECIALTY: Dermatology, Allergy and Immunology FOCUS: Urticaria, Mastocytosis, Angioedema, Pruritus, Skin Infections, Allergic Disea

  63. Slide 63: Pipeline Strategy & Update

    Slide 63: Pipeline Strategy & Update

    Pipeline Strategy & Update Bradford A. Youngblood, PhD Head of Research & Preclinical Development – Allakos Inc.

  64. Slide 64: Pipeline Strategy Focused on Targeting Siglecs

    Slide 64: Pipeline Strategy Focused on Targeting Siglecs

    Pipeline Strategy Focused on Targeting Siglecs Current Landscape is Mediator Focused Inhibitory Receptors on Key Pathogenic Cells Most molecules in development for inflammation target individual cytokines implicated in disease While effective, most mediators are produced by a small number of pathoge

  65. Slide 65: Allakos Pipeline

    Slide 65: Allakos Pipeline

    Antibody Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration Milestone Lirentelimab (Anti-Siglec-8) Eosinophilic Gastritis (EG) and/or EoD Topline data announced Dec 2021 Eosinophilic Duodenitis (EoD) Topline data expected Q3 2022 Eosinophilic Esophagitis (EoE) Topline data

  66. Slide 66: AK006 Program

    Slide 66: AK006 Program

    AK006 Program

  67. Slide 67: Mast Cells are Pathogenic Cells that are Non-Selectively Targeted

    Slide 67: Mast Cells are Pathogenic Cells that are Non-Selectively Targeted

    Mast Cells are Pathogenic Cells that are Non-Selectively Targeted Mast cells express numerous activating receptors on their cell surface that contribute to disease Siglec-6 is an inhibitory receptor selectively expressed on mast cells that has unique immunomodulatory activity Siglecs represent attra

  68. Slide 68: Siglec-6 Is Selectively Expressed on Human Tissue Mast Cells

    Slide 68: Siglec-6 Is Selectively Expressed on Human Tissue Mast Cells

    Siglec-6 Is Selectively Expressed on Human Tissue Mast Cells Gating Strategy for Immune Cells in Human Tissue Siglec-6 Expression Profile Siglec-6 represents a selective mast cell inhibitory receptor n=15 human donors

  69. Slide 69: AK006: Siglec-6 mAb That Selectively Targets Mast Cells

    Slide 69: AK006: Siglec-6 mAb That Selectively Targets Mast Cells

    AK006: Siglec-6 mAb That Selectively Targets Mast Cells AK006 is a humanized IgG1 agonistic Siglec-6 mAb that selectively targets mast cells High affinity mAb selected for potent Siglec-6 agonism Broad mast cell inhibition via Siglec-6 ITIM agonism Reduction of mast cells via Fc-dependent mechanism

  70. Slide 70: AK006 Inhibits Mast Cell Activation in Human Tissues

    Slide 70: AK006 Inhibits Mast Cell Activation in Human Tissues

    AK006 Inhibits Mast Cell Activation in Human Tissues IgE-Activated Human Tissue Mast Cells AK006 potently inhibits IgE-mediated mast cell activation Human Tissue Mast Cell Activation Assay n=3 human donors

  71. Slide 71: AK006 Completely Protects Against Systemic Anaphylaxis in Humanized Mice

    Slide 71: AK006 Completely Protects Against Systemic Anaphylaxis in Humanized Mice

    AK006 Completely Protects Against Systemic Anaphylaxis in Humanized Mice Active Tryptase Mast Cell-Specific Mediators Histamine Systemic Anaphylaxis AK006 inhibits IgE-mediated mast cell activation in vivo Humanized Mouse Model of Anaphylaxis Chymase * p < 0.01; n=7 mice/group

  72. Slide 72: AK006 Inhibits KIT-mediated Mast Cell Activation

    Slide 72: AK006 Inhibits KIT-mediated Mast Cell Activation

    AK006 Inhibits KIT-mediated Mast Cell Activation in Siglec-6 Transgenic Mice Mast Cell Activation AK006 inhibits KIT- and IgE-mediated mast cell activation SCF, stem cell factor; * p < 0.01; n=7-8 mice/group Cytokines and Chemokines CD63 IL-6 TNF CXCL1 / GRO- CCL2 / MCP-1

  73. Slide 73: AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice

    Slide 73: AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice

    AK006 Inhibits Allergic Contact Dermatitis in Siglec-6 Transgenic Mice Skin Inflammation AK006 reduces skin inflammation via mast cell inhibition * p < 0.01; n=6-7 mice/group DNFB, 2,4-dinitrofluorobenzene Cytokines in Ex Vivo-Cultured Ears Epicutaneous sensitization with DNFB Day 0 ISO or AK006 Day

  74. Slide 74: AK006 Reduces Human Tissue Mast Cells

    Slide 74: AK006 Reduces Human Tissue Mast Cells

    AK006 Reduces Human Tissue Mast Cells Dosing Study in Humanized Mice AK006 inhibits mast cells and reduces mast cell numbers Ex Vivo Human Tissue Mast Cells Day 0 Day 15 Dosed with AK006 or AK002 or ISO Control MC numbers Day 5 Day 10 Peritoneal Mast Cells Mast Cells in Tissue * p < 0.01; (left) n=3

  75. Slide 75: Summary

    Slide 75: Summary

    Summary AK006 is a humanized IgG1 agonistic Siglec-6 mAb that selectively inhibits mast cells and reduces their numbers Represents the first mast cell-specific molecule in development Avoids off-target effects of non-selective mast cell molecules Unique MOA that differentiates from other mast cell-t

  76. Slide 76: Closing Remarks

    Slide 76: Closing Remarks

    Closing Remarks Baird Radford & Robert Alexander, PhD CFO and CEO – Allakos Inc.

  77. Slide 77: Expected Cash Runway into Early Q1 2024

    Slide 77: Expected Cash Runway into Early Q1 2024

    Expected Cash Runway into Early Q1 2024 Cash and Investments Balance as of Dec 31, 2020 $659 Million Full Year 2021 Cash Used $235 Million Balance as of Dec 31, 2021 $424 Million Realigned operating and expense structures to enable our lirentelimab and AK006 development plans Completed a 35% reducti

  78. Slide 78: Development Timeline

    Slide 78: Development Timeline

    Development Timeline Program 2021 2022 2023 2024 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q Eosinophilic Esophagitis (EoE) Eosinophilic Gastritis (EG) and/or EoD Atopic Dermatitis (AD) Chronic Spontaneous Urticaria (CSU) IV SC Ph 3 EG/EoD Study Ph 3 EoD Study Ph 3 EoE Study (SC) – expected initiation Ph 2/3 E

  79. Slide 79: Q&A

    Slide 79: Q&A

    Q&A

  80. Slide 80: Thank You

    Slide 80: Thank You

    Thank You

  81. Slide 81: References

    Slide 81: References

    References Rothenberg ME, Mishra A, Collins MH, et al. Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol. 2001 Dec;108(6):891-4. Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up

Source: SEC EDGAR · 8-K/A filed Feb 15, 2022

More decks from Allakos Inc